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Background: The aim of this randomized controlled triple blind trial was to compare the efficacy of clonidine with 
dexamethasone versus ondansetron with dexamethasone for postoperative pain, nausea and vomiting prevention 
in orthognathic surgery patients. 
Material and Methods: In this clinical trial study, 30 consecutive patients with skeletal class III deformities were 
candidates for orthognathic surgery in Qaem hospital, Mashhad University of medical sciences, Mashhad, Iran 
from March to November 2017. These subjects were randomly assigned to two equal number groups, ondansetron 
or clonidine.  Patients received either oral ondansetron 8mg or oral clonidine 150μg as premedication, 1 hour be-
fore the surgery (both dissolved in 20 cc of water). Also both groups received intravenous dexamethasone 8mg (1 
hour preoperatively and every 4 hours intraoperatively). 
Results: In this study, a total of 30 patients (14 males and 16 females) with a mean age of 23.9 ± 3.9 were investigat-
ed. The incidence of postoperative nausea in women was more than men (p=0.003), also the correlation between 
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Introduction
Postoperative Nausea and Vomiting (PONV) is con-
sidered as a distressing and challenging complication 
of post-surgery and anesthesia (1-7). It is of greater 
concern than even postoperative pain, to the surgi-
cal patients(1-3). PONV may lead to serious surgical 
complications such as wound dehiscence or surgical 
site bleeding, hematoma, aspiration and choking prob-
ability, water and electrolyte disturbances resulting in 
increased healthcare costs due to lower patient satisfac-
tion and delayed hospital discharge (1-5,8,9).
It is believed that PONV has multifactorial origin (1-
3,5,7,8). These factors can be divided into patient-re-
lated characteristics (age, gender, obesity and smoking 
status as well as history of motion sickness or previous 
PONV), anesthetic-related (volatile anesthetics, intra-
operative use of opioid and blood transfusion) and sur-
gical-related factors (type and duration of surgery and 
use of postoperative analgesic opioids) (1-3,5,7,8). 
The estimated incidence of PONV after general surger-
ies would be approximately 40-60%, which can reach up 
to %80 in high risk patients underlying the importance 
of its prevention and control by surgeons and anesthe-
tists. Regarding the recent articles, the estimated PONV 
incidence during the first 24 h after orthognathic sur-
geries is stated to be 40-68% (1-3,9). 
PONV prevention for orthognathic surgical patients 
remains an under-investigated domain of clinical care 
to maximize patient safety and satisfaction (1,2). Max-
illomandibular elastic tractions and intermaxillary 
wires following orthognathic surgery can magnify the 
anxiety, agitation and risk of aspiration associated with 
PONV, which may be life threatening event in maxil-
lofacial patients (1,10). 
As a matter of fact, administration of antiemetic drugs 
to prevent and manage PONV is an important tool that 
should be properly used (1,2,4,5,8,11). Considering the 
multifactorial etiology of this complication, multimodal 
therapy is recommended for prevention of PONV in 
high risk patients. Therefore various drug combinations 
have been tried and found to be effective for this issue, 
albeit they had some side effects (1,2,5,12).
Clonidine is a α2-adrenergic agonist drug, playing an 
important role as a sedative in anesthesia and pain con-
trol which would act more effectively than opioids and 
benzodiazepines in decreasing central and peripheral 
blood pressure with lower adverse effects (5,6,13). It has 
been reported to prevent the sympatho-adrenergic re-
sponse to anesthesia, suppress cardiovascular response 
to laryngoscopy and reduce anesthetic and analgesic 
requirements (13,14). It also provides preoperative seda-
tion, postoperative analgesia and perioperative hemo-
dynamic stability (5,6,10,11,13,14).
In addition, recent investigations have demonstrated 
that premedication with oral clonidine is successful in 
reducing the PONV after strabismus, ear and breast 
cancer surgeries as well as appendectomy and thyroid 
surgeries due to its multifactorial influence on decreas-
ing stress, general sympathetic tone and catecholamine 
release (5-7,10,11,13).
Ondansetron is an antagonist for serotonin (5HT3: 5-hy-
droxy tryptamine subtype 3) receptor. It is well estab-
lished for prophylaxis of PONV as oral and intravenous 
preparation (5,15). Due to its strong anti-vomiting effect 
without complications such as bradycardia and extra-
pyramidal syndrome, ondansetron is applied in several 
studies to reduce PONV after chemotherapy, laparosco-
py and strabismus surgeries as well as ENT and thyroid 
surgeries (4,5,8,16,17). Interestingly, the recent reports 
declared ondansetron might attach to µ opioid receptor 
as an antagonist that leads to analgesic effects especial-
ly in neuropathic pains (15,18-20).
It is noteworthy that intravenous Dexamethasone has 
been combined with other drugs for successful prophy-
laxis of PONV, according to multimodal protocol in re-
cent investigations (4,5,8,12).
The epidemiology of PONV is well described in the lit-
erature with regard to abdominal, gynecological, plastic, 
ENT and other types of general surgeries (4,6-8,11,12). 
However only limited studies specifically analyzed the 
prevalence of PONV, related risk factors and its manage-
ment among orthognathic surgery patients (1-3). PONV 
prevention for orthognathic surgical patients remains an 
under-investigated domain of clinical care (1,2).
To the best of our knowledge, no article comparing 
the efficacy of Ondansetron versus Clonidine on post-
the incidence of PON and the surgery duration ≥ 3 hours was statistically significant (p = 0.050). The frequency of 
postoperative nausea (PON) in the ondansetron group was less than clonidine (53.3% vs 73.3% respectively). There 
was no postoperative vomiting (POV) in the ondansetron group, but 6.7% of cases in clonidine group suffered POV. 
Post-operative nausea in ondansetron group occurred significantly later than clonidine (525.0±233.2 vs 100.0±34.0 
min; p <0.001). On the other hand, the incidence time of post-operative severe pain or in other word the analgesia 
time in clonidine group was significantly more than ondansetron one (875/0±68/5 vs 614.3±159.1 min; p <0.001). 
Conclusion: Ondansetron with dexamethasone premedication was more effective in controlling PONV after orthog-
nathic surgery compared to clonidine with dexamethasone group. 
Key words: Postoperative nausea and vomiting, ondansetron, clonidine.
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operative pain, vomiting and nausea management after 
orthognathic surgeries has been published up to now, 
except Shilpa’s study after thyroidectomy (5).
Hence, we decided to perform this randomized triple 
blind clinical study to investigate and compare the ef-
ficacy of oral ondansetron with intravenous dexametha-
sone versus oral clonidine with intravenous dexametha-
sone for prevention of postoperative pain and PONV 
after orthognathic surgeries.
Material and Methods
A triple-blind randomized clinical trial was carried out. 
The protocol of this study was approved by the Ethics and 
Research Committee of Mashhad University of Medical 
Sciences (IR.mums.sd.REC.1394.176), and was regis-
tered in IRCT under the code IRCT2017012922697N2. 
Guidelines of the Declaration of Helsinki were followed 
in this research.
After obtaining written informed consent, all the 
healthy systemic patients (ASA I, II) who had the skel-
etal class III deformities with the age range of 18 to 45 
and BMI less than 30 kg/ (non-obese) from any gender 
or race were included in this study. These cases were 
candidates for orthognathic surgery in maxillofacial 
surgery department of Qaem Hospital of Mashhad 
(Iran), from March to November 2017.
Subjects with serious medical conditions (ASA≥III), 
history of previous motion sickness or recent emesis, 
hypersensitivity and allergy to any study drugs were ex-
cluded from this study. In addition, the patients showing 
severe hypotension and bradycardia during the surgery 
and requiring blood transfusion intra-operatively or 
ICU post-operatively as well as those who refused the 
follow-up checkups were excluded too. None of the pa-
tients were smokers.
All of the operations were carried out by a single surgeon 
and anesthesiologist using the same protocol. A pre-an-
esthetic and pre-operative evaluations were done in all 
patients with a detailed history, routine laboratory and ra-
diographic investigations. Also the type of deformities and 
surgical treatment plans as well as Patients’ ages, sexes 
and BMIs were determined and recorded in checklist.
The cases were divided into two equal number groups 
(ondansetron or clonidine) by balanced block random-
ization. In line with Consort guidelines, random codes 
were applied according to the number of patients and 
drugs, so each patient was randomly categorized with 
a code. Allocation concealment was performed using 
sequentially numbered opaque sealed envelopes. 
The first group was given 150μg clonidine tablet dis-
solved in 20 cc water orally 60 min before surgery. The 
second group was given 8mg ondansetron tablet similar 
to the first group dissolved in 20cc water at the same time.
In addition, 8 mg intravenous dexamethasone was in-
jected for both groups, 60 min preoperatively.
All the packages were labeled and numbered randomly. 
Assigning the patients to either of the treatment groups 
randomlyand administration of the drugs was done by 
the student who was not involved in the surgery and an-
esthesia procedure.
Prior to the surgery each patient was given a package 
and the aim of the study was explained to the patients 
at the start, but they were not told who would receive 
which drug. The randomization code was concealed 
from the surgeon, study investigator (nursing staff) and 
patients. The codes kept in a secure location until the 
end of the study.  
In other word, neither the patient nor the surgeon and 
study investigator were aware of the pharmaceutical 
packages content (triple- blind, randomized clinical 
trial). However the anesthesiologist and student were 
aware of the drugs and groups in order to prevent the 
inadvertent intra and postoperative events. 
Patients were kept NPO (nil per os) for 8 hours preoper-
atively. Both groups received the same standard intrave-
nous drug regimens for hypotensive general anesthesia: 
0.3 mg/kg midazolam, 2.5 mg/kg remifentanyl, 1 mg/
kg lidocaine, and 100-200 µg/kg/min propofol infusion 
intravenously were employed to stabilize blood pres-
sure and heart rate in optimal range. Neuromuscular 
relaxation was achieved with 0.5 mg/kg atracurium, the 
patients also received 3-4 cc/kg/h Ringer solution in or-
der to achieve proper hydration goal.
As a matter of fact the volatile anesthetics and nitrous 
oxide were avoided in favor of a total intravenous anes-
thetic (TIVA) based on propofol and remifentanil infu-
sions titrated by the anesthesia care team. Morphine and 
codeine were avoided intraoperatively and postopera-
tively to prevent PONV probability.
All subjects underwent the same surgical technique (bi-
lateral sagittal split osteotomy for mandibular setback, 
Lefort I osteotomy for maxillary advancement and ge-
nioplasty if necessary). Duration of surgery was noted 
in checklist.
Patients were monitored by pulse oximetry, electro-
cardiography, thermal probe and capnography, also 
the heart rate and mean arterial pressure (MAP) were 
checked carefully during the operation in order to find 
out any bradycardia or sever hypotension status. To re-
verse the anesthesia at the end of surgeries, muscle re-
laxant effect was neutralized by Neostigmine (0.04 mg/
kg IV) and Atropine (0.02 mg/kg IV). 
Both groups underwent similar antibiotic therapy with 
intravenous Cefazolin (1gr, 1hour preoperatively and 
every 6 hours postoperatively). Additionally 8 mg intra-
venous Dexamethasone was prescribed in both groups 
(1hour preoperatively, every 4 hours intraoperatively 
and every 8 hours postoperatively); in order to reduce 
edema, inflammation and pain.
As it was proved in previous studies that above men-
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tioned drugs were individually stronger than placebo 
for PONV prevention, therefore the placebo was elimi-
nated in the present study and the authors just compared 
the efficacy of ondansetron-dexamethasone versus 
clonidine-dexamethasone.
No blood transfusion were required during the opera-
tion. Postoperatively, all patients were transferred to the 
maxillofacial surgery ward for 24 hours.No oral intake 
was allowed for patients in the first 6 hours after recov-
ery from anesthesia, so the dextrose-saline serum was 
administered intravenously. 
PONV and pain was assessed and observed by special-
ly trained nursing staff without knowledge treatment 
groups. (Every 15-30 min in recovery room and later 
once every hour in the surgical ward for the first post-
operative day.)
Post-operative pain was measured subjectively, using a 
visual analog scale (VAS), in such a way that pain was 
recorded from 0 (representing no pain) to 10 (represent-
ing the most severe pain).The investigator documented 
the severe pain (VAS≥7) incidence in checklist. 
For the first 24 hours after anesthesia, the presence or 
absence of nausea and vomiting (by simply yes or no) 
was assessed in both groups. Nausea was defined as the 
subjectively unpleasant sensation associated with the in-
voluntary attempts to vomit without discharge of stom-
ach contents, whereas vomiting was defined as an actual 
discharge of gastric contents from the mouth. Any side 
effects in postoperative period were also recorded.
Metoclopramide (0.2 mg/kg, intravenously) was used as 
a rescue antiemetic. It was administered when patients 
vomited or when nausea was intense, with more than 15 
min duration. For cases who faced intolerable severe pain 
(VAS≥7), Apotel (1g, intravenously) was prescribed as a 
rescue analgesic. The time when these rescue drugs were 
prescribed was also noted in check list.
The patients discharged in the second day after surgery 
with stable vital signs. Finally the checklists were en-
coded and sent for statistical analyses. 
In the next stage of data analysis, decoding was per-
formed. Data were analyzed using SPSS for Windows 
(V. 16, SPSS Inc., Chicago, IL). Qualitative variables 
were expressed as percentage while quantitative vari-
ables stated as mean ± SD (standard deviation). We em-
ployed Mann–Whitney, student’s t-test, chi-square and 
Fisher’s exact test for analysis. P-value less than 0.05 
were considered statistically significant.
Results
In the present study, a total of 30 patients including 14 
males (46/7%) and 16 females (53/3%) with average age 
of 23/9±3/9 and age range of 18 to 32 years were inves-
tigated during 9 months. All of the cases had class III 
jaw deformity.
8 females (53.3%) and 7 males (46.7%) were studied 
in each group (ondansetron or clonidine), therefore the 
distribution of sex was similar in both. Chi-Square test 
manifested no statistical difference in sex distribution 
between clonidine and ondansetron group (p=1.00).
Age average in ondansetron group was 23.4±3.8 years 
and in clonidine group was 24.4±4.0. Therefore, age dif-
ference between our study groups was insignificant ac-
cording to T-test (p=0.490).
Diagram 1 illustrates the frequency of post-operative 
severe pain, postoperative nausea and vomiting in the 
study groups (Fig. 1).
Fig. 1. The comparison of postoperative severe pain, nausea and vomiting frequency in ondansetron versus clonidine group.
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The frequency of severe post-operative pain (VAS≥7) 
requiring rescue doses of analgesics in each group was 
14 cases (93.3%), which is entirely identical in both 
groups regarding the ficher’s exact test (P=1.00).
The frequency of post-operative nausea (PON) in on-
dansetron and clonidine groups was 8 (53.3%) and 11 
cases (73.3%) respectively. Even though the frequency 
of PON in the ondansetron group was less than cloni-
dine, but it did not have any significant difference be-
tween two groups according to the chi-Square test 
(p=0.256). 
Interestingly, the post-operative vomiting (POV) was 
not observed in ondansetron group (0%), but only 1 pa-
tient had POV in clonidine group (6.7%). However, the 
ficher’s exact test manifested no statistical difference 
for POV between groups (p=1.00).
Table 1 depicts that there was no significant differ-
ence in BMI (Body mass Index) between study groups 
(p=0.903). Although duration of surgery in ondansetron 
 
  
Variable Drug type N
o 




BMI Ondansetron 15 24.4±2.25 21.4-28.4 T*=0.12 
P=0.903 Clonidine 15 24.3±1.74 21.4-27.3 
Duration of surgery (minutes) Ondansetron 15 166.0±60.8 60-240 T=0.73 
P=0.468 Clonidine 15 148.7±68.1 60-240 
Time of post-operative severe 
pain incidence (minutes) 
Ondansetron 14 614.3±159.1 360-900 Z**=4.2 
P<0.001 Clonidine 14 875.0±68.5 780-960 
The time of post-operative 
nausea incidence (minutes) 
Ondansetron 8 525.0±233.2 360-900 Z=3.6 
P<0.001 Clonidine 11 100.0±34.0 60-150 
Mean arterial pressure during 
surgery (mmHg) 
Ondansetron 15 102.0±7.3 90-115 Z=3.2 
P<0.001 Clonidine 15 93.0±5.6 85-105 
Table 1. The comparison of BMI, Duration of surgery, Mean arterial pressure during surgery and time of postoperative severe 
pain and nausea between ondansetron and clonidine group.
*: Independent T-test result **: Mann-Whitney test result
group (166±60.8 min) was a little more than clonidine 
group (148.7±68.1 min), but they had no significant sta-
tistical difference (p=0.468). 
Post-operative nausea in ondansetron group occurred 
significantly later than clonidine group patients, regard-
ing the Mann-Whitney test (525.0±233.2 vs 100.0±34.0 
min; p<0.001). On the contrary, the incidence time of 
post-operative severe pain or in other words the anal-
gesia time in clonidine group (875.0±68.5 min) was sig-
nificantly more than ondansetron one (614.3±159.1 min) 
according to the Mann-Whitney test (p<0.001).
Patients’ mean arterial pressure during surgery in Cloni-
dine group was significantly lower than Ondansetron one 
(93.0±5.6 vs 102.0±7.3 mmHg; p<0.001) Table 1.
Diagram 2 illuminates the comparison of the average 
duration of surgery, the mean incidence time of nausea 
and severe pain (analgesia time) between ondansetron 
and clonidine group (Fig. 2).
63.3% of all patients who underwent orthognathic sur-
Fig. 2. The comparison of mean arterial pressure, mean incidence time of postoperative nausea and severe pain (analgesia 
time) in ondansetron versus clonidine group.
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geries with more than 3 hours duration showed PON. 
Furthermore 80% of patients in clonidine group and 
46.7% in ondansetron confronted nausea in the case of 
surgery duration more than 3h. Chi-Square test showed 
the significant correlation between postoperative nau-
sea incidence and surgery duration longer than 3hours 
(P=0.050).
The incidence of PON in females appeared to be 73.7% 
and in males 26.3%. In other words, the incidence of 
postoperative nausea in women was significantly more 
than men according the chi-Square test (p=0.003). How-
ever the incidence of severe postoperative pain turned 
out to be 53.6% in women and 46.4% in men, which had 
no significant difference (P=1.00).
Also by BMI increase in this study, the incidence rate 
of nausea rose. There was a significant relation between 
BMI and PON in accordance with the ficher’s exact test 
analysis (P<0.001).
Table. 2 depicts that the surgery type in 20 cases (66.6%) 
was bimaxillary orthognathic surgery (Bimax), from 
which 7 cases (23.3% of total) had genioplasty too. The 
isolated one jaw orthosurgery was done for 10 patients 





Study groups Orthognathic surgery types 
 
Total 
A B C D E  
Ondansetron No 3 1 7 3 1 15 
%  20 6.7 46.7 20 6.7 100 
Clonidine No 3 1 6 4 1 15 
%  20 6.7 40 26.7 6.7 100 
Total No 6 2 13 7 2 30 
%  20 6.7 43.3 23.3 6.7 100 
Table 2. The frequency of orthognathic surgery types in study groups. 
A: Isolated Mandibular BSSO osteotomy B: Isolated Maxillary lefort I osteotomy, C: Bimaxil-
lary orthosurgery , D: Bimaxillary Osteotomy + Genioplasty  E: Maxillary lefort I Osteotomy + 
Genioplasty.  
Fischer’s exact test result, P=1.00
osteotomy and 4 cases (13.4%) had maxillary lefort I os-
teotomy surgeries. In addition, 9 (30%) of all 30 patients 
required genioplasty (Table 2).
Ficher’s exact test analysis revealed both clonidine and 
ondansetron groups roughly resembled one another 
in regard to frequency of orthognathic surgery types 
(P=1.00).
PON prevalence in bimax orthosurgery was 68.4% 
(36.8% alone and 31.6% with genioplasty), also nausea 
frequency in isolated maxillary lefort I was 21% (10.5% 
alone and 10.5% with genioplasty) and in isolated man-
dibular osteotomy was 10.5%. On the other hand, the 
severe postoperative pain was more frequent in bimax 
cases (67.9%), followed by isolated mandibular osteoto-
my (21.4%) and then isolated maxillary lefort I (10.7%) 
respectively. However these mentioned differences 
were not statistically significant. (P=0.204 and 0.336). 
The Table 3 shows the postoperative pain and nausea 
prevalence for each surgery type including genioplasty 
in detail (Table 3).
It should be noted that no major adverse events such as 
bradycardia or severe hypotension were observed in ei-
ther group. The patients had no problem in follow ups.
 
 
Variables Orthognathic surgery types Total 
A B C D E 
Post-operative 
nausea incidence 
Yes No 2 2 7 6 2 19 
% 10.5 10.5 36.8 31.6 10.5 100 
No No 4 0 6 1 0 11 
% 36.4 0 54.5 9.1 0.0 100 




Yes No 6 1 12 7 2 28 
 % 21.4 3.6 42.9 25.0 7.1 100 
No No 0 1 1 0 0 2 
 % 0 50 50.0 0 0 100 
Ficher’s exact test result, P=0.336 
	
Table 3. The postoperative pain and nausea prevalence for each orthognathic surgery type. 
A: Isolated Mandibular BSSO osteotomy B: Isolated Maxillary lefort I osteotomy, C: Bi-
maxillary orthosurgery , D: Bimaxillary Osteotomy + Genioplasty  E: Maxillary lefort I 
Osteotomy + Genioplasty.
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Discussion
Postoperative nausea and vomiting (PONV) is one of 
the most undesirable complications related to general 
anesthesia and appears to be the second common reason 
for long-term hospitalization (2,3,5-7,11,16).
It complicates the post-anesthesia and postsurgical care 
and also can result in adverse consequences such as 
dehydration, esophageal rupture, wound dehiscence, 
bleeding, hematoma, aspiration of gastric contents and 
possible death (1-5,8). This issue must receive special 
attention as PONV causes severe post-operative pain, 
prolongs post-anesthesia care unit (PACU) stay increas-
es patients’ dissatisfaction and is of high importance 
due to costs and problems imposing on patients and 
health care system (1-5,8,11,21,22).
In spite of significant advances in the area of postopera-
tive nausea and vomiting (PONV) and the introduction 
of new antiemetic agents, the incidence of PONV may 
be as high as 30-92% in surgical population depending 
on the type of surgery and patients’ risk factors (2,3).
Although many studies have shown the highest prev-
alence of PONV among ophthalmologic (80%), ear 
(70%), intra-abdominal (40 to 70%) and laparoscopic 
(40 to 77%) surgeries, few reports have focused on this 
complication after oral and maxillofacial surgeries, es-
pecially orthognathic procedures (1,3,9). It should be 
noted PONV prevention for orthognathic surgical pa-
tients remains an under-investigated domain of clinical 
care (1,2).
The literatures demonstrate a high incidence of both 
PON and POV after orthognathic operation, even after 
the last updated consensus guidelines for the manage-
ment of PONV after general surgery in 2007 (1,2).
Silva et al. in 2006 performed the large retrospective 
review of PONV after orthognathic surgery on 514 pa-
tients. They found it had a high prevalence in the first 24 
hours comparing to other maxillofacial operations with 
a particularly high frequency (56%) after bimaxillary 
osteotomies (3).
Philips et al. studied 204 subject after orthognathic sur-
geries in 2015. They reported the incidence of PON and 
POV without premedication was 67% and 27% respec-
tively (1).
Unfortunately only limited literatures analyzed the 
prevalence of PONV and related risk factors as well as 
the proper management specifically in orthognathic sur-
gery field up to now (1-3,10,23). Hence, further studies 
are needed to develop effective protocols for preventing 
this common and unpleasant problem in maxillofacial 
patients with intermaxillary fixation.
The etiology of PONV is complex and involves a num-
ber of interrelated pathways (1,6,7). Regarding the sys-
tematic reviews, the risk factors including the younger 
age, female gender, obesity (BMI more than 30 kg/) and 
nutritional habits as well as previous history of emesis 
and motion sickness are the independent predictors for 
PONV. Moreover, the surgery type and duration (lon-
ger than 2-3 hours), the anesthesia drugs particularly 
volatile agents and opioid analgesics can lead to PONV 
emergence, especially after orthognathic surgeries (1-
3,5-8,9). 
In fact, the multifactorial etiology of PONV is better 
addressed by multimodal approach regarding the recent 
articles (1-3,5,8,9). Administration of antiemetic drugs 
to prevent or mange the PONV is an important tool that 
should be properly used (1-5,8,9). It has been suggested 
that the use of more than one prophylactic antiemetic 
drug, acting at different receptor sites is more effec-
tive than the use of a single drug especially in high risk 
patients, however there is no consensus regarding the 
optimal prophylactic antiemetic regimen nowadays (1-
5,8,9).
Regarding to mentioned facts, a multimodal protocol 
(e.g. ondansetron-dexamethasone or clonidine-dexa-
methasone) was applied in the present study and also 
volatile anesthetic was avoided. It is well established 
that the use of perioperative opioid narcotics would be 
associated with PONV (1,5,24,25), therefore the effec-
tive postoperative pain control would be an important 
issue in maxillofacial field for patient comfort and safe-
ty.
Although it is proven many routine drugs such as meto-
clopramide and anti-histamines may decrease PONV, 
but they might cause adverse effects such as xerosto-
mia, hypotension, excess sedation, delusion and extra 
pyramidal symptoms (15,16,21).
Various researches proved that the prophylactic influ-
ence of Ondansetron (5HT3 receptor antagonist) is 
more effective than Metoclopramide (Dopamine recep-
tor antagonist) on PONV, especially in those who un-
dergo chemotherapy (4,15,24,26). It does not cause the 
side effects such as Dystonia, bradykinesia and extrapy-
ramidal syndrome(15,16,21). Ondansetron can prevent 
PONV for 6-12 h after surgery (5).
The recent studies declared ondansetron might attach to 
µ opioid receptor as an antagonist which leads to anal-
gesic effects especially in neuropathic pains. It is note-
worthy that prescribing ondansetron as an analgesic in 
contrast to opioid narcotics, includes no major adverse 
effects (15,18-20).
Clonidine is a α2 agonist which reduces blood pressure 
centrally and peripherally and prevent cardiovascular 
reactions due to sympathoadernergic response resulting 
from intubation and laryngoscopy procedures (5,7,10). It 
also plays sedative and hypotensive roles for anesthesia 
with less cost and complications compared to benzodi-
azepines and opioids (5-7,10,11,14). 
Khezri et al. reported that clonidine provided a better 
pain relief after cesarean section compared to fentanyl 
(14).
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Since a high sympathetic tone and catecholamine re-
lease may trigger nausea and vomiting, a general reduc-
tion in sympathetic outflow caused by clonidine could 
also have contributed to the reduction of PONV (5,7,10).
It has onset of action 0.5-1 h and longer duration of ac-
tion of up to 12h (5,10).Although the bradycardia and se-
vere hypotension are the clonidine complications (5,10), 
but no cases in our study confronted them. 
Various researches reported the positive impact of 
clonidine prescription on hemodynamic stability and 
reducing the incidence of PONV after ear, strabismus 
and breast cancer surgeries as well as appendectomy 
and thyroid surgeries (5-7). 
Mohammadi and Tabrizi et al. stated the advantages 
of clonidine in their articles. It proposes hemodynamic 
stability during orthognathic surgery and rhinoplasty 
by decreasing the bleeding and reducing mean arterial 
pressure (10).
Dexamethasone is a Glucocorticoid with antiemetic im-
pact especially in chemotherapy patients. It can reduce 
tissue inflammation and reduce the ascending parasym-
pathetic impulses to the vomiting center. Regarding the 
literatures, dexamethasone has a good prophylactic ef-
fect for PONV when given one hour prior to surgery 
(4,5,8).
Bano and Fazal wadood et al. reported the administra-
tion of ondansetron plus dexamethasone is more effec-
tive than ondansetron or dexamethasone separately for 
PONV management (8), thus we applied this combined 
protocol in our research. In addition, as it was stated 
before in articles, multifactorial etiology of PONV is 
better addressed by multimodal approach (1,2,5,12). 
To the best of our knowledge, our study was the first 
triple blind clinical trial which compared the efficiency 
of clonidine versus ondansetron premedication on post-
operative pain and PONV after orthognathic surgeries. 
Considering the inclusion and exclusion criteria and af-
ter omitting the confounding factors, the current study 
included 30 class III healthy patients (2 groups of 15 
cases). This sample size was identical to Mohammadi et 
al. study which studied the effect of clonidine premedi-
cation on hemodynamic status in orthognathic surger-
ies (10).
The study drugs dose selections for premedication 
(clonidine, ondanstron and dexamethasone), their pre-
scription protocol and also the rescue antiemetic and 
analgesic drugs selection (metoclopramide and Apotel) 
to control PONV and pain were adopted from Shipla, 
Taheri and Alizadeh et al. studies (5-7).
The intravenous Apotel, which is a non-opioid analge-
sic and does not have increasing effect on nausea and 
vomiting, was prescribed in cases that confronted post-
orthosurgical severe pain in current study, relevant to 
Shipla et al. and Alizadeh et al. studies (5,6). 
While the PONV occurs primarily within the first 24 
hours postoperatively which can lead to significant mor-
bidity (3,5,6), therefore the assessment of pain, nausea 
and vomiting was performed in the first 24 hours post-
operatively in our research, which was in compliance 
with Taheri, Alizadeh, Bano, Fazal Wadood, Shilpa 
and Elhakim et al. studies (5,6,8). Also the intervals 
in which we evaluated these variables postoperatively 
were in harmony with Shipla and Elhakim et al. articles 
(5).
Since previous experiments by Taheri, Elhakim, Aliza-
deh and Bano et al. revealed effectiveness of either 
clonidine or ondansetron alone, compared with placebo 
on PONV and pain reduction, therefore we did not uti-
lize placebo in the present study (5-8,10). In fact, re-
garding the high possibility of POV after orthognathic, 
we did not include a placebo group for ethical reasons 
(5). Instead, similar to Shipla et al. study on thyroid-
ectomy patients, we compared effects of oral clonidine 
or ondansetron premedications (both combined with IV 
dexamethasone) on PONV and pain after orthognathic 
surgery (5).
Regarding the retrospective study of Philips et al., the 
incidence of PON and POV without premedication was 
67% and 27% respectively after orthognathic surgeries 
(1).
In our study, postoperative nausea (PON) in ondan-
setron-dexamethasone group was occurred in 53.3% 
cases compared to clonidine-dexamethasone in 73.3%, 
while postoperative vomiting (POV) incidence in on-
dansetron and clonidine groups was 0% and 6.7% re-
spectively, in this research. Hence, it can be concluded 
both drugs would decrease POV effectively however 
ondansetron was more effective in nausea prevention.
Our research findings highlight that the analgesia time 
in clonidine group was significantly more than ondanse-
tron one (875.0±68.5 min vs 614.3±159.1 min; p<0.001). 
This was very similar to Shipla et al. study results after 
thyroidectomy, as they reported the analgesia time in 
clonidine and ondansetron groups was 919 vs 642 min-
utes (1). Regarding to literature, clonidine has a longer 
duration of action up to 12h (5,6).
Post-operative nausea in ondansetron group occurred 
significantly later than clonidine group in our study, 
(525.0±233.2 vs 100.0±34.0 min; p<0.001). It was in 
agreement with Shilpa et al. study which demonstrated 
the incidence time of PON in ondansetron group was 
within 360-720 min and in clonidine within 60-120 min 
after thyroidectomy (5). It was similar finding to the 
present research, as the time range of PON incidence in 
our study was within 360-900 minutes in ondansetron 
versus 60-150 postoperatively in clonidine group. Re-
garding to literatures, ondansetron can prevent PONV 
for 6-12 h postoperatively (5,15).
Mean arterial pressure (MAP) was averagely 93±5/6 
mmHg in Clonidine group and 102±7/3 mm Hg in On-
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dansetron. However both MAP values were appropriate 
from anesthetic point of view, but MAP was significant-
ly lower in Clonidine group (p<0.001) that corresponds 
to Mohammadi and Tabrizi et al. studies since cloni-
dine leads to hemodynamic stability, hypotension and 
decreases bleeding during operation (10).
Regarding Apfel, Brooks and Silva et al. studies, PONV 
occurs more frequently in youngeradults which was 
correspondent to our findings (2,3,9). 
Controversies are existed regarding the BMI and PONV 
relation, as Philips et al. believed that BMI≥30 cor-
related with PONV while some authors like Gan and 
brooks et al opposed any correlations (1,2,27). However 
the relation between BMI and nausea was significant 
in our experiment. (The more BMI, The more PONV 
incidence.) 
Nausea incidence in females was observed significantly 
more than males. It is well-known that adult males are 
less likely to experience PONV than females due to 
fluctuation in women hormone levels during the men-
strual cycle, which matched with Philips, Silva and Shi-
pla et al. studies (1,3,5).
The significant relationship was found between post-
operative nausea incidence and surgery duration longer 
than 3hours due to accumulation of emetogenic factors 
related to general anesthesia.This correlation was simi-
lar to Silva and Brooks et al. results which suggested 
that the obese patients might have a higher prevalence 
of PONV, especially after long operations (longer than 
3 hours) (2,3).
In current study, PON incidence in patients who had Bi-
maxillary orthoganatic surgery (Bimax) was more than 
single jaw surgeries. Also Nausea incidence in maxil-
lary osteotomy was observed more than mandibular 
osteotomy surgery. Sever pain was more frequent in 
Bimax patients, following by isolated mandibular oste-
otomy and then maxillary lefort I surgery.
The results were relevant to Philips, Silva and Brooks 
et al. reports (1-3). One explanation of these results may 
be the greater average length of surgery time and tissue 
trauma for bimaxillary surgeries versus isolated max-
illary or mandibular surgeries.It is emphasized in the 
literature that the longer the surgery, the higher the inci-
dence of PONV will be (1-3,5,6).
Actually isolated maxillary surgery showed a higher 
prevalence of PONV than did mandibular procedures 
alone, despite the fact that the length of the surgery was 
similar in both groups. It can be explained by greater 
postoperative bleeding, blood swallowing probability 
and the hypotensive anesthesia which is often used dur-
ing maxillary osteotomies (1-3,10).
In addition, genioplasty as a complementary operation 
works as an additional and increasing factor for dura-
tion of surgery and bleeding risk which will result in 
higher PONV incidence (1-3). 
Mandibular osteotomy puts more pressure on musculo-
skeletal components of temporomandibular joint, there-
fore the pulled muscles cause higher post-operative pain 
(1-3,10). 
Also, other treatment options  such as 5HT3 antago-
nists, such as granisetron, palonosetron, and ramose-
tron, are used for PONV prophylaxis (28,29). 
Limitations and suggestions
One of the present study limitations was the sample 
size, so we suggest recruiting a larger sample size with 
higher number of orthognathic surgery patients for fu-
ture studies to signify the correlation between other 
factors. Another limitation was the fact that this study 
was a single center research so low number of surgeons 
participated. Future studies will work best if they gain 
more maxillofacial surgeons’ attentions and compare 
diverse treatment centers. 
In addition, PONV and pain were only monitored dur-
ing the first 24 hours postoperatively in present re-
search. This could be better if patients’ check-ups con-
tinued more, albeit Silva et al. determined that PONV 
would occur most commonly within the first 24 hours 
postoperatively in orthognathic patients (3).
Despite the limitations, the outcome of this study was 
quite satisfying since it proposed an effective multi-
modal protocol for prevention of PONV and post-oper-
ative severe pain after orthognathic surgeries
Conclusions
Our study showed that ondansetron with dexametha-
sone premedication was more effective in controlling 
PONV after orthognathic surgery compared to cloni-
dine with dexamethasone group. However, the analge-
sia time was longer with clonidine than ondansetron 
group, but on the contrary there is no significant differ-
ence between the ondansetron and clonidine group in 
terms of postoperative severe pain occurrence.
Therefore premedication with oral ondansetron ac-
companied by intravenous dexamethasone could be 
proposed as an effective multimodal protocol to reduce 
both PONV and post-operative severe pain in orthogna-
thic surgeries without major and significant side effects.
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